Autor:
Lorca, M.
Morales-Verdejo, C.
Vásquez-Velásquez, D.
Andrades-Lagos, J.
Campanini-Salinas, J.
Soto-Delgado, J.
Recabarren-Gajardo, G.
Mella, J.
The wide tissue distribution of the adrenergic β3 receptor makes it a potential target for the treatment of multiple pathologies such as diabetes, obesity, depression, overactive bladder (OAB), and cancer. Currently, there is only one drug on the market, mirabegron, approved for the treatment of ...
Enlace original:
http://repositorio.unab.cl/xmlui/handle/ria/8959
Lorca, M.
,
Morales-Verdejo, C.
,
Vásquez-Velásquez, D.
,
Andrades-Lagos, J.
,
Campanini-Salinas, J.
,
Soto-Delgado, J.
,
Recabarren-Gajardo, G.
,
Mella, J.
,
[Structure-activity relationships based on 3D-QSAR CoMFA/CoMSIA and design of aryloxypropanol-amine agonists with selectivity for the human β3-adrenergic receptor and anti-obesity and anti-diabetic profiles]
,
Structure-activity relationships based on 3D-QSAR CoMFA/CoMSIA and design of aryloxypropanol-amine agonists with selectivity for the human β3-adrenergic receptor and anti-obesity and anti-diabetic profiles
